tiprankstipranks
Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA

Iovance Biotherapeutics Stock Price & Analysis

1,092 Followers

IOVA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.18 - $27.96
Previous Close$9.79
Volume2.12M
Average Volume (3M)2.64M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$424.46M
Total Debt (Recent Filing)$8.14M
P/E Ratio-4.1
Beta0.53
Next EarningsNov 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.40
Shares Outstanding157,800,581
R-Squared0.01
Standard Deviation0.24
10 Day Avg. Volume2,300,240
30 Day Avg. Volume2,643,744
P/B Ratio3.27
P/S RatioN/A
P/CF RatioN/A
P/FCF Ratio-5.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside142.19% Upside
Rating ConsensusStrong Buy
Alpha0.03
Number of Analyst Covering8


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

IOVA FAQ

What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $6.18 and its highest was $27.96 in the past 12 months.
    What is Iovance Biotherapeutics’s market cap?
    Currently, no data Available
    When is Iovance Biotherapeutics’s upcoming earnings report date?
    Iovance Biotherapeutics’s upcoming earnings report date is Nov 09, 2022 which is in 44 days.
      How were Iovance Biotherapeutics’s earnings last quarter?
      Iovance Biotherapeutics released its earnings results on Aug 04, 2022. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.606 by -$0.024.
        Is Iovance Biotherapeutics overvalued?
        According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Iovance Biotherapeutics pay dividends?
          Iovance Biotherapeutics does not currently pay dividends.
          What is Iovance Biotherapeutics’s EPS estimate?
          Iovance Biotherapeutics’s EPS estimate is -$0.64.
            How many shares outstanding does Iovance Biotherapeutics have?
            Iovance Biotherapeutics has 157,800,580 shares outstanding.
              What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
              Iovance Biotherapeutics reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.606. Following the earnings report the stock price went down -2.871%.
                Which hedge fund is a major shareholder of Iovance Biotherapeutics?
                Among the largest hedge funds holding Iovance Biotherapeutics’s share is Perceptive Advisors LLC. It holds Iovance Biotherapeutics’s shares valued at 131M.

                  ---

                  Iovance Biotherapeutics Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  4
                  The Iovance Biotherapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Iovance Biotherapeutics Inc

                  Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis